

# GrayBug Presenting at the 40th Annual Meeting & Exposition of the Controlled Release Society

/EINPresswire.com/ Product overview delivered at popular "Soapbox Sessions"

[GrayBug](#) has been selected to present this summer at the Controlled Release Society's 40th Annual Meeting & Exposition on Sunday, July 21, 2013, in Honolulu, Hawaii.



"We are pleased to have been chosen to give an overview of GrayBug's cutting edge technologies for ocular drug delivery at this year's annual meeting at the very popular Soapbox Sessions on Innovation Sunday," says Christy Wyskiel, COO of GrayBug. "We will be reviewing our two platform technologies for long-term controlled drug delivery into the eye following injection as well as provide an overview of our pipeline for diseases that affect vision, including age-related macular degeneration and glaucoma."

## About the Soapbox Sessions:

The Soapbox Sessions are a well-attended and very interactive part of the Controlled Release Society's "Innovation Sunday" program. These sessions attract large audiences from pharmaceutical and biotechnology companies, venture capitalists, and others who are interested in exploring recent innovations and tools.

## About GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company's lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye. These technologies were co-developed by the lead founder of GrayBug, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at Johns Hopkins University with joint appointments in four other Hopkins departments including Biomedical Engineering, in collaboration with top ophthalmology clinician-scientists from the Wilmer Eye Institute, Dr. Peter Campochiaro and Dr.

Peter J. McDonnell. For more information, please visit [www.graybug.com](http://www.graybug.com).

Media Contact:

Christy Wyskiel

GrayBug LLC

410.779.1236

<http://www.graybug.com>

Press Release courtesy of Online PR Media: <http://bit.ly/YxnOvn>

---

This press release can be viewed online at: <https://www.einpresswire.com/article/149410461>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.